Condition
Stage III Hilar Cholangiocarcinoma AJCC v8
Total Trials
3
Recruiting
0
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Active Not Recruiting2
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05564403Phase 2Active Not Recruiting
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
NCT06178588Phase 2Active Not Recruiting
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
NCT06420349Phase 1Terminated
NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
Showing all 3 trials